Pfizer, BioNTech Stocks Rise After Final Vaccine Update

Pfizer will seek FDA approval within days

Assistant Editor
Nov 18, 2020 at 10:18 AM
facebook twitter linkedin

Once again, Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) are dominating headlines, after the two drugmakers announced their coronavirus vaccine candidate was 95% effective as its final result. Pfizer also said it plans to seek U.S. Food and Drug Administration (FDA) approval within days. 

As a result of today's announcement, PFE is up 3.2%, last seen trading at $37.27. Pfizer stock soared to annual highs last time we reported on the company's vaccine update. Though it pulled back slightly since then, the equity has risen above the $37 level once again, with a floor of support near $35. Additionally, PFE is just shy of its year-to-date breakeven mark. 

Meanwhile, BNTX is up 4.5% to trade at $90.80. Similarly, when we last checked on BioNTech stock following the vaccine update, the equity surged to an all-time high of $115. While the equity has pulled back over the last three sessions, the 40-day moving average has been a steady leg of support. In fact, the security remains up 163% in 2020.

In the options pits, bulls are still running amuck, with BNTX and PFE seeing 50-day call/put volume ratios of 3.73 and 8.51, respectively, at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). Both ratios show calls handily outpacing puts, indicating a heavy preference for bullish over bearish bets of late.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners